Short- and Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis and Muscle Loss
Respiration · 2025-12-04 · 105 (6) · 633-641
DOI: 10.1159/000549895 ↗Abstract
Introduction: Loss of muscle mass and sarcopenia are associated with poor prognosis in chronic respiratory illnesses and are currently emerging as coexisting conditions that deserve attention in patients with idiopathic pulmonary fibrosis (IPF). However, the exact impact of muscle changes in this deadly disease is not entirely understood. Our study aimed to investigate the role of muscle loss/myosteatosis assessed by computed tomography in the short- and long-term survival of patients with IPF treated with antifibrotics. Methods: Ninety-six patients with IPF (16 females, 80 males) were retrospectively enrolled between March 2014 and December 2022. Demographic, functional, and radiological data were collected at diagnosis. Area and density of the paravertebral muscle at the level of the 12th thoracic vertebra were collected, and myosteatosis was defined as Hounsfield Unit (Hu) value
EUVIMED